APA (7th ed.) Citation

SZ, U., T, F., V, H., NJ, B., CP, V., M, B., . . . S, Z. (2025). Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nature medicine, 31(4), 1366. https://doi.org/10.1038/s41591-025-03581-2

Chicago Style (17th ed.) Citation

SZ, Usmani, et al. "Author Correction: Daratumumab Plus Bortezomib, Lenalidomide and Dexamethasone for Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: The Randomized Phase 3 CEPHEUS Trial." Nature Medicine 31, no. 4 (2025): 1366. https://doi.org/10.1038/s41591-025-03581-2.

MLA (9th ed.) Citation

SZ, Usmani, et al. "Author Correction: Daratumumab Plus Bortezomib, Lenalidomide and Dexamethasone for Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: The Randomized Phase 3 CEPHEUS Trial." Nature Medicine, vol. 31, no. 4, 2025, p. 1366, https://doi.org/10.1038/s41591-025-03581-2.